August Newsletter
Golden Ticket

BMS and MBC BioLabs 2021 Golden Ticket Competition – Deadline approaching
The Bristol Myers Squibb Golden Ticket Contest at MBC BioLabs is a contest that awards 2 lab benches for 1 year to 2 innovative biotech start-ups pursuing research in the fields of oncology, hematology, immunoscience, cardiovascular disease, neuroscience or fibrotic diseases that best meet the judging criteria. Applications can be submitted through August 17, 2021 at 11:59 PM EST.
Apply for the 2021 Servier Spark Awards – Summer edition
As part of our commitment to therapeutic progress to serve patients' needs, Servier is fostering early-stage innovation and engaging with those who are championing revolutionary ideas in multiple areas of oncology, neuroscience, immuno-inflammation as well as next generation of drug discovery technologies and platforms. Servier welcomes any interested startup companies to submit proposals by August 20, 2021 at 11:59 PM EDT.
Click to apply

FCDI Scientific Session #1:
"How to Model Diseases of Aging in a Dish: Alzheimer's, Parkinson's & Age-related Macular Degeneration"

FUJIFILM Cellular Dynamics (FCDI), founded in 2004 by Dr. Jamie Thompson, provides a reliable commercial source of iPSC-derived terminally differentiated cells. These human cells are amenable to highly translational cell-based assays to bridge the gap between basic cell biology and clinical research.

In this Scientific Session, FCDI will review its neural portfolio, focusing on diseases of aging. Published and preliminary data will be presented demonstrating how FCDI's disease models have been used to study neurodegenerative diseases, in particular Alzheimer's disease (AD) and Parkinson's disease (PD). We will examine the benefits of co-culturing iCell® neuronal cells with iCell glia products, and demonstrate how stimulation of these glia products induces the secretion of pro- and anti-inflammatory molecules. Additionally, we will show how iCell Retinal Pigment Epithelial (RPE) cells have been used to model both wet and dry forms of age-related macular degeneration (AMD). Finally, we will review examples of successful drug screens using these disease-in-a-dish models. Together, this presentation will provide a proof-of-concept and conceptual foundation for the study of age-related diseases using FCDI's healthy donor-derived neural portfolio, engineered disease models, and diseased donor-derived cells.

Date: August 26th, 2021 from 12–2PM
Lunch will be served

Click to Register
Thermo Fisher Scientific & MBC Biolabs HoloLens Pilot Program

We are delighted to announce the Thermo Fisher HoloLens Pilot Program at MBC BioLabs.

To learn more about the program and how HoloLens works and how it can support you, please join us on Wednesday and Thursday, August 11 and 12, 2021 from 12-3PM for an in-person lunch event at MBC BioLabs @ 953 Community Room and MBC BioLabs @ 930 Brittan respectively. The event consists of a seminar followed by a hands-on demonstration of the technology.

Date: August 11th & 12th, 2021 from 12-3PM
Lunch will be served

Click to Register
MBC BioLabs & YCombinator:
Future Founders - Robert Bell, PhD, Telo Therapeutics

Robert Bell is the co-founder and CEO of Telo TherapeuRcs Inc., an oncology therapeutics company that utilizes novel precision medicine approaches to reverse cancer cell immortality. The company's core pipeline focuses on cancer cell-specific inhibitors of telomerase. Dr. Bell earned his BS from Boston College and his PhD in Biomedical Sciences from the University of California, San Francisco. Telo was founded in 2015 based on Dr. Bell's graduate work and was incubated at MBC Biolabs in San Francisco. In June, Telo raised $6 Million in Series Seed financing that will be used to develop its small molecule inhibitors towards clinical candidates directed towards Glioblastoma and other cancer types with high unmet need.

Date: August 30th 11:30AM–12:30PM

Click to register
New Companies

Tradewind Bioscience
Tradewind BioScience (TWB) is a company dedicated to creating novel, innovative therapeutics for the most aggressive, difficult to treat cancers. Their first therapeutic is a multifaceted attack antibody for cancer. What this means is that it works through multiple modes of action to the detriment of malignant cells.
PHINOMICS uses circular DNA, an early marker of genetic change and physiological response, to diagnose disease and radically improve human health. By isolating and sequencing the circular genome (the "Circulome"), they solve a genetic puzzle that unlocks a universal "stage-zero" diagnostic for disease. At scale, circulome data will revolutionize diagnostics and identify new therapies
MBC BioLabs, Enabling Awesome